ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company”) reported that its Executive Director, Chief Executive Officer, and Chairman of the Board, Dr. Tian Wenzhi, acquired 50,000 H shares in the open market on December 3, 2025. The purchase price averaged approximately HK$6.6258 per share, representing about 0.01% of the Company’s total issued share capital at the time of the transaction.

Following this purchase, Dr. Tian holds a total of 116,134,090 shares, comprising 26.91% of the Company’s total issued shares. He remains optimistic regarding the Group’s development prospects and potential growth. Dr. Tian indicated that, subject to relevant regulations, further share acquisitions may be considered in the future. The Company advised shareholders and potential investors to exercise caution when dealing in its securities.